GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.

Everest and Gilead Announce Positive Phase 3 Results of Breast Cancer Drug

by Fujie Tham
Share To

Shanghai’s Everest Medicines announced that its licensing partner, Gilead Sciences reported positive results from the primary analysis of the Phase 3 TROPiCS-02 study of Trodelvy in metastatic breast cancer patients. The study compared Trodelvy with chemotherapy in HR+/HER2- metastatic breast cancer patients who received prior endocrine therapy, CDK4/6 inhibitors, and two to four lines of chemotherapy.

The data presented at the annual meeting of the American Society of Clinical Oncology (ASCO) showed progression-free survival for the Trodelvy group of 5.5 months compared with 4 months for chemotherapy patients. Most HR+/HER2- metastatic breast cancers will ultimately become resistant to endocrine therapy, treatment is then limited to chemotherapy, with declining response, and decreased quality of life. The study demonstrated that at the one-year mark, three times as many patients were progression-free when treated with Trodelvy.

Related article: Shanghai’s Everest Medicines Licenses COVID-19 Oral Antivirals from Singapore’s National Drug Discovery Platform 

 

Tumor-Targeting Antibody-Drug Conjugate

 

Trodelvy (sacituzumab govitecan-hziy) is a drug connected with a Trop-2 directed antibody. Trop-2 is a cell surface antigen highly expressed in various tumor types, including in over 90% of breast and bladder cancers. Trodelvy’s proprietary design delivers potent activity to both Trop-2 expressing cells and the microenvironment.

“In TROPiCS-02, we enrolled heavily pre-treated patients with metastatic breast cancer who had disease progression following multiple lines of chemotherapy. To observe a clinically meaningful reduction in the risk of disease progression or death in these patients with limited treatment options is remarkable. Sacituzumab govitecan-hziy will be an important potential future treatment option for these patients” said Dr. Hope Rugo, Professor of Medicine and Director of Breast Oncology and Clinical Trials Education at the University of California San Francisco Comprehensive Cancer Center

Under a 2019 licensing agreement with Gilead Sciences’ Immunomedics, Everest Medicines has exclusive rights to develop, register, and commercialize Trodelvy for all cancer indications in Greater China, South Korea, and certain Southeast Asian countries.

Trodelvy is currently approved for locally advanced or metastatic urothelial cancer and unresectable locally advanced or metastatic triple-negative breast cancer in the US. The drug’s sales for Q4 2021 were $118 million, and is expected to reach $2 billion in 2026.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
AI-Powered Blood Test Achieves 98% Accuracy in Early Breast Cancer Detection
2024-12-11
Antibody-Drug Conjugates: Connecting Drugs to Cancer Cells and Unlocking Billions in Market Opportunities
2024-11-06
Highlights from ESMO 2024: Key Oncology Advances from Major Pharmaceutical Companies
2024-09-19
LATEST
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top